Two HIFs may be better than one

Slides:



Advertisements
Similar presentations
The Hypoxic Tumour Microenvironment: Ets-1 Promotes Hypoxia Inducible Factor-  Target Specificity Chet Holterman, PhD Dr. Stephen Lee.
Advertisements

Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Wiesener.
The Function of VHL and pVHL Protein VHL is a tumor suppressor gene on chromosome 3 Helps to regulate and destroy the alpha subunit of hypoxia-inducible.
Mutations in the retinoblastoma tumor-suppressor gene (RB1) contribute to inherited and sporadic cancers. The figure indicates that cell context affects.
Kidney cancer: Identification of novel targets for therapy
Targeting HIF2α in Clear-Cell Renal Cell Carcinoma
Angiogenesis and hepatocellular carcinoma
A new therapeutic antibody masks ErbB2 to its partners
Volume 76, Issue 9, Pages (November 2009)
Regulation of the Cell Cycle & Cancer
Louise E. Glover, Sean P. Colgan  Gastroenterology 
von Hippel-Lindau Disease
Concept 18.5: Cancer results from genetic changes that affect cell cycle control The gene regulation systems that go wrong during cancer are the very same.
Genetics of Cancer.
New Research on Kidney Cancer: Highlights from Urologic and Oncologic Congresses in 2006  Jean-Jacques Patard, Eric Lechevallier, Belén Congregado Ruiz,
VHL Inactivation: A New Road to Senescence
Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer
A Time to Divide: Does the Circadian Clock Control Cell Cycle?
The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease
Management of advanced renal cancer
p53 and Apoptosis: It's Not Just in the Nucleus Anymore
Cell signaling and cancer
Kidney Cancer: Now Available in a New Flavor
Wild-Type p53: Tumors Can't Stand It
Volume 13, Issue 1, Pages 1-2 (January 2008)
Basic Research in Kidney Cancer
VEGF-B Improves Metabolic Health through Vascular Pruning of Fat
Molecular mechanisms of diabetic renal hypertrophy
Apoptosis-targeted therapies for cancer
A new therapeutic antibody masks ErbB2 to its partners
Current and Future Trends in the Treatment of Renal Cancer
Angiogenesis and hepatocellular carcinoma
Engaging the vascular component of the tumor response
Volume 3, Issue 4, Pages (April 2003)
Understanding the Importance of Smart Drugs in Renal Cell Carcinoma
Targeting HIF2α in Clear-Cell Renal Cell Carcinoma
Volume 76, Issue 9, Pages (November 2009)
Hypoxia-Inducible Factors, Stem Cells, and Cancer
The Hypoxic Response: Huffing and HIFing
miR-34a and the Cardiomyopathy of Senescence: SALT PNUTS, SALT PNUTS!
VEGF-B Improves Metabolic Health through Vascular Pruning of Fat
Lung Cancer Resets the Liver’s Metabolic Clock
Volume 3, Issue 1, Pages (January 2013)
IDH1 Mutations in Gliomas: When an Enzyme Loses Its Grip
A New FOXO Pathway Required for Leukemogenesis
Tumor Metabolism: MAGE-A Proteins Help TRIM Turn Over AMPK
Volume 54, Issue 5, Pages (June 2014)
Apoptosis-targeted therapies for cancer
Thymoma and Thymic Carcinoma: Molecular Pathology and Targeted Therapy
Low oxygen stimulates the immune system
John D. Gordan, Craig B. Thompson, M. Celeste Simon  Cancer Cell 
Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells
Mutations of von Hippel-Lindau Tumor-Suppressor Gene and Congenital Polycythemia  Yves Pastore, Katerina Jedlickova, Yongli Guan, Enli Liu, James Fahner,
Apoptosis Cell Volume 108, Issue 2, Pages (January 2002)
Autocrine IL-6 Signaling: A Key Event in Tumorigenesis?
Rajnish Mehrotra, Joel D. Kopple, Marsha Wolfson  Kidney International 
Intratumoral hypoxia, radiation resistance, and HIF-1
Inflammation and hypoxia in the kidney: friends or foes?
A common pathway for genetic events leading to pheochromocytoma
Role reversal: Brain insulin and liver STAT3
Volume 4, Issue 4, Pages (April 2009)
Regulation of Angiogenesis and Tumorigenesis by Signal Transduction Cascades: Lessons from Benign and Malignant Endothelial Tumors  Robert Klafter, Jack.
Update on the Medical Treatment of Metastatic Renal Cell Carcinoma
Volume 1, Issue 3, Pages (April 2002)
GA blocks HIF activity and reduces HIF target expression.
Volume 3, Issue 1, Pages (January 2003)
Volume 32, Issue 1, Pages 3-5 (July 2017)
Kidney Cancer: Now Available in a New Flavor
Christopher G. Abraham, Joaquín M. Espinosa  Cancer Cell 
Volume 3, Issue 4, Pages (April 2003)
Presentation transcript:

Two HIFs may be better than one Tiffany Seagroves, Randall S Johnson  Cancer Cell  Volume 1, Issue 3, Pages 211-213 (April 2002) DOI: 10.1016/S1535-6108(02)00048-X

Figure 1 The pathway from VHL to renal cell carcinoma The steps from loss of VHL to tumorigenesis are becoming more defined. Solid arrows and lines represent the correlations between known genetic pathways and corresponding specific genes that are affected by loss of VHL; dotted arrows and lines represent relationships that have been described, but remain uncertain. In summary, loss of VHL permits constitutive expression of HIF-1α and HIF-2α, and possibly other yet to be identified targets of proteasomal degradation. In this issue of Cancer Cell, Kondo et al. (2002) and Maranchie et al. (2002) have described the importance of HIF-2α with respect to growth of renal cell carcinoma; however, it remains unknown whether other HIFα subunits contribute to RCC via redundant or overlapping functions. Overexpression of HIFα subunits results in the induction of several classical HIF-1 target genes, even in the absence of hypoxia, such as Glut-1, VEGF, and PGK. These target genes are in turn responsible for stimulating the angiogenic and metabolic changes that manifest as increased tumor microvessel density and acidosis, hallmarks of a variety of tumor types. The role that hypoxia plays with respect to cell cycle progression/arrest and/or apoptosis is less well-defined. Nevertheless, it is likely that dysregulation at any point in the hierarchy contributes to the development of renal cell carcinoma, as well as other malignancies observed in patients with VHL mutations. Cancer Cell 2002 1, 211-213DOI: (10.1016/S1535-6108(02)00048-X)